Navigation Links
Landmark Clinical Trial Shows Surgery and Stenting Equally Safe and Effective at Preventing Stroke
Date:5/26/2010

Physicians now have more options in tailoring treatments for patients at risk for stroke.

(Vocus) May 26, 2010 -- After nine years of investigation, the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST), conducted in part by University at Buffalo Neurosurgery, shows that two different procedures designed to prevent future strokes are safe and effective overall. In the trial of 2,502 participants, carotid endarterectomy (CEA), a surgical procedure considered the gold standard prevention treatment, was compared to carotid artery stenting (CAS), a newer and less invasive procedure that involves expanding a small device in the artery to widen the blocked area and capture any dislodged plaque. The trial was funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH). Results of the study appear today in the online first edition of the New England Journal of Medicine.*

The CREST trial was performed at 117 medical centers in the United States and Canada and is considered one of the largest randomized stroke trials ever conducted. University at Buffalo Neurosurgery played a key role in the investigation as a leading enroller and the designated CAS training site for more than 200 surgeons, neurosurgeons, radiologists, and cardiologists participating in the study. University at Buffalo Neurosurgery is one of the busiest neuroendovascular laboratories and one of the most experienced and successful practitioners of carotid stenting in the world.

Results of the CREST trial show that the overall safety and efficacy of the two procedures was largely the same, with equal benefits for men and women, and for patients who had previously had a stroke and for those who had not. However, when the investigators looked at the numbers of heart attacks and strokes, they found differences: there were more heart attacks in the surgical group (2.3 percent compared to 1.1 percent in the stenting group) and more strokes in the stenting group (4.1 percent versus 2.3 percent for the surgical group) in the weeks following the procedure.

The study also found that the age of the patient made a difference. For patients aged 69 years and younger, stenting results were slightly better. In fact, the younger the patient was at the time of procedure, the larger the benefit of stenting. Conversely, for patients older than 70, surgical results were slightly superior. As the age of the patient increased so did the benefits of surgery over stenting.

According to L.N. Hopkins, M.D., chairman of University at Buffalo Neurosurgery, “The question is no longer whether we can use stents to prevent strokes. Now, it’s determining the best candidates.”

Stroke, the third leading cause of death in the United States, is caused by an interruption of blood flow to the brain by a clot or bleeding. Because carotid arteries on each side of the neck are the major source of blood flow to the brain, the buildup of cholesterol in the wall of the carotid artery, called atherosclerotic plaque, is a leading cause of stroke.

One of the strengths of the study, according to investigators, is that CREST was conducted in a variety of real-world settings, including large and small public and private hospitals, and by a number of different types of specialists, including neurosurgeons, cardiologists, neuroradiologists, interventional radiologists, and vascular surgeons. Most importantly, physicians had to demonstrate a high degree of proficiency and safety in order to participate in the trial. The study found no significant differences in the outcomes, no matter what type of medical specialist performed the stenting procedure.

“For a patient considering carotid treatment, the most important thing is a second opinion,” says Dr. Hopkins. “When the risk of a procedure is stroke, you want to be sure to choose a well-trained, experienced physician—no matter his or her specialty.”

CREST investigators point out that the rate of stroke and death was the lowest ever reported in a large stroke prevention trial, and while CEA has a proven record and long-term durability, both CAS and CEA are safe and useful tools in the right setting for stroke prevention, especially as advances in technology and patient selection continue to improve each procedure. CAS may be particularly useful for younger patients and for those patients who require a less invasive, less expensive treatment option.

“The CREST trial was a large, complex undertaking that will provide the medical community with important information on the comparative effectiveness of these two procedures. NINDS is committed to long-term follow up of this group of patients, which will help us learn even more about how best to prevent stroke,” said Story Landis, Ph.D., NINDS director.

Partial funding for the study was supplied by Abbott, of Abbott Park, Ill., the maker of the stents.

About UBNS

University at Buffalo Neurosurgery, Inc. (UBNS) is an academic neurosurgical group and leading regional referral center for cerebrovascular disorders run by a distinguished team of neurosurgical specialists and subspecialists committed to superior patient care, resident education, and translational research. UBNS diagnoses and treats a wide range of neurological conditions, including but not limited to aneurysms; stroke; back and neck pain; epilepsy; Parkinson’s disease; hydrocephalus; and tumors of the brain, spine, and skull base. It is also the only neurosurgical group in Western New York with FDA approval to conduct device-related clinical trials for acute stroke. Visit www.ubns.com for more information.

About the NINDS/NIH

The National Institute of Neurological Disorders and Stroke (NINDS) is the nation’s leading funder of research on the brain and nervous system. The NINDS mission is to reduce the burden of neurological disease – a burden borne by every age group, by every segment of society, by people all over the world.

The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases.

 
  • Brott,TG et al., Stenting Compared to Endarterectomy for Treatment of Carotid Artery Stenosis, New England Journal of Medicine, online first edition May 26, 2010.

###

Read the full story at http://www.prweb.com/releases/2010/05/prweb4053054.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Landmark Textbook Aims to Improve Clinician, Consumer Understanding of Lesbian Health
2. DNC Chairman Tim Kaine Calls Senate Vote Historic, Says Landmark Health Reform Bill Is a Victory for the American People
3. Senate Passes Landmark Health Care Reform Bill
4. New edition of landmark stroke textbook
5. California to Examine Health Impacts of Landmark Cap-and-Trade Program
6. Foodborne Illness Costs U.S. $152 Billion Annually, Landmark Report Estimates
7. Landmark Legal Foundation to File Suit to Stop Presidents Health Plan if Slaughter Rule is Used
8. China's Forbidden City Leads Landmark Climate Action for Earth Hour
9. Endometriosis Foundation of America to Present Landmark Scientific Symposium in NYC
10. Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program
11. FDA Issues Guidance to Help Streamline Medical Device Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Landmark Clinical Trial Shows Surgery and Stenting Equally Safe and Effective at Preventing Stroke
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is ... competitive pricing. Verisys through its FACIS and other services maintains the ... actions. , “We are delighted to be able to offer these various products ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: